Stockscreener 앱 받기
0.471
9.25%
-0.048
시간 외 거래:
.49
0.019
+4.03%
전일 마감가:
$0.519
열려 있는:
$0.519
하루 거래량:
374.01K
Relative Volume:
1.54
시가총액:
$29.09M
수익:
-
순이익/손실:
$-76.57M
주가수익비율:
-0.2298
EPS:
-2.05
순현금흐름:
$-70.74M
1주 성능:
-27.56%
1개월 성능:
-18.72%
6개월 성능:
-64.32%
1년 성능:
-21.50%
1일 변동 폭
$0.47
$0.519
1주일 범위
$0.47
$0.675
52주 변동 폭
$0.47
$1.79
Passage Bio Inc Stock (PASG) Company Profile
명칭
Passage Bio Inc
전화
(267) 866-0312
주소
ONE COMMERCE SQUARE, PHILADELPHIA, PA
PASG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PASG | 0.471 | 29.09M | 0 | -76.57M | -70.74M | -2.05 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-03 | 개시 | Rodman & Renshaw | Buy |
| 2022-03-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-19 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-07-01 | 개시 | Raymond James | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-03-04 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-02-04 | 개시 | Guggenheim | Buy |
| 2021-01-25 | 개시 | Wedbush | Outperform |
| 2021-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 개시 | Citigroup | Neutral |
| 2020-08-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2020-03-24 | 개시 | Cowen | Outperform |
| 2020-03-24 | 개시 | Goldman | Buy |
| 2020-03-24 | 개시 | JP Morgan | Overweight |
모두보기
Passage Bio Inc 주식(PASG)의 최신 뉴스
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateOn November 13, 2024, Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary dise - Defense World
Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World
BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024UNAUDITED – On November 13, 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX) disclosed its financial results for the third quarter ending September 30, 2024. Within the detai - Defense World
MRC Global Inc. Enters into Fifth Amended and Restated Loan Agreement - Defense World
Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World
Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Tetra Tech Reports Record Fiscal 2024 and Fourth Quarter ResultsOn November 13, 2024, Tetra Tech, Inc. (NASDAQ: TTEK) released its financial results for the fourth fiscal quarter and the fiscal year ended September 29, 2024. According to the report - Defense World
Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World
Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
374Water Inc. Reports Third Quarter 2024 Results and Business Update - Defense World
Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MyChesCo
Passage Bio stock hits 52-week low at $0.54 amid market challenges - Investing.com
Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace
Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results - MSN
Vestal Point Capital, LP Increases Stake in Passage Bio Inc - GuruFocus.com
Passage Bio Achieves Milestones in Gene Therapy Trials - Yahoo Finance
Passage Bio Shows Progress in Gene Therapy Trials - TipRanks
PASGPassage Bio, Inc. Latest Stock News & Market Updates - StockTitan
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio's Q3 Shows Progress: Clinical Trial Advances, Cash Runway Extended to 2026 | PASG Stock News - StockTitan
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MyChesCo
Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! - MSN
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference - StockTitan
R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, on Gene Therapy for APOE4 Homozygous Alzheimer Disease - CGTLive™
Data Roundup: October 2024 Features Update for TCR-Based Autologous Cell Therapy in Melanoma, the First Clinical Demonstration of Therapeutic RNA Editing in Humans, and More - CGTLive™
Passage Bio reports advances in gene therapy for dementia - Investing.com
Gene therapy shows promise in frontotemporal dementia study - Investing.com
Gene therapy shows promise in frontotemporal dementia study By Investing.com - Investing.com South Africa
Passage Bio reports advances in gene therapy for dementia By Investing.com - Investing.com South Africa
Passage Bio Presents Preclinical and Interim Clinical Data - GlobeNewswire
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship - MSN
Will Passage Bio See An Uplift? Frontotemporal Dementia Trial Data Holds The Key - RTTNews
PASG stock touches 52-week low at $0.55 amid market challenges - Investing.com
Plexxikon, Inc. - Scrip
Passage Bio Inc [PASG] 10% Owner makes an insider purchase of 39,300 shares worth 27903.0. - Knox Daily
Director Mayson Howard John sale 4,000 shares of Ovintiv Inc [OVV] - Knox Daily
Passage Bio Inc (PASG) Stock: A Year of Highs and Lows - The InvestChronicle
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MSN
Passage Bio stock hits 52-week low at $0.57 amid market challenges - Investing.com Australia
Jim Wilson’s new gene therapy company Gemma is getting up to $100M from Brazil - Head Topics
Passage Bio stock hits 52-week low at $0.57 amid market challenges By Investing.com - Investing.com South Africa
Frontotemporal Dementia Pipeline 2024: Clinical Trials - openPR
Frontotemporal Dementia Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Alector, Oncolys BioPharma, Denali Therapeutics, Passage Bio - Barchart
Daniela van Eickels, MD, PhD, MPH, on Addressing Unmet Needs in Autoimmune Disease With Cell Therapy - CGTLive™
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment - MyChesCo
Passage Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MyChesCo
Passage Bio Inc (PASG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):